Approval · Notice of Compliance 26353 · 2021
RILUTEK: Notice of Compliance 26353
Issued July 29, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26353
- Date
- July 29, 2021
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Additional manufacturing site involving production of an intermediate. Change in the manufacturing process for the drug substance.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RILUTEK | Not yet assigned | — |
Medicinal ingredients
- RILUZOLE 50 MG per TAB